{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:45:04Z","timestamp":1792431904713,"version":"4.5.0"},"reference-count":222,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T00:00:00Z","timestamp":1569369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"DOI":"10.3389\/fgene.2019.00868","type":"journal-article","created":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T02:21:10Z","timestamp":1569378070000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":249,"title":["Development and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders"],"prefix":"10.3389","volume":"10","author":[{"given":"Alireza","family":"Shahryari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Saghaeian Jazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi","family":"Razavi Nikoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Nazari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaheh Sadat","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Burtscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Javad","family":"Mowla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Lickert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,9,25]]},"reference":[{"key":"B1","unstructured":"U.S. Food & Drug Adminstartion, YESCARTA (axicabtagene ciloleucel), Product information"},{"key":"B2","unstructured":"European Medicines Agency, Zalmoxis (Allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (DLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)), Product Information"},{"key":"B3","unstructured":"European Medicines Agency, Strimvelis (autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence), Product information"},{"key":"B4","unstructured":"U.S. Food & Drug Adminstration, KYMRIAH (tisagenlecleucel), product information"},{"key":"B5","doi-asserted-by":"publisher","first-page":"535","DOI":"10.2217\/imt.15.15","article-title":"Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors","volume":"7","author":"Abken","year":"2015","journal-title":"Immunotherapy"},{"key":"B6","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1517\/14656566.2016.1145664","article-title":"11TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathies","volume":"17","author":"Adams","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"key":"B7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"1Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12883-017-0948-5","article-title":"12Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy","volume":"17","author":"Adams","year":"2017","journal-title":"BMC Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"737","DOI":"10.15252\/emmm.201707573","article-title":"Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products","volume":"9","author":"Aiuti","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ppul.24203","article-title":"Health outcomes in spinal muscular atrophy type 1 following AVXS\u2010101 gene replacement therapy","volume":"54","author":"Al\u2010Zaidy","year":"2019","journal-title":"Pediatr. Pulmonol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1128\/AAC.40.9.2004","article-title":"Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA","volume":"40","author":"Anderson","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"B12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13395-017-0141-y","article-title":"A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys","volume":"7","author":"Andre","year":"2017","journal-title":"Skeletal Muscle"},{"key":"B13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2147\/ODRR.S39979","article-title":"33An update on gene therapy for the treatment of lipoprotein lipase deficiency","volume":"4","author":"Andrew","year":"2013","journal-title":"DovePress"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1128\/AAC.37.9.1945","article-title":"Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region","volume":"37","author":"Azad","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.5301\/ejo.5001060","article-title":"Pegaptanib: choroidal neovascularization in patients with age-related macular degeneration and previous arterial thromboembolic events","volume":"28","author":"Battaglia Parodi","year":"2018","journal-title":"Eur. J. Ophthalmol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1161\/01.CIR.97.12.1114","article-title":"Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia","volume":"97","author":"Baumgartner","year":"1998","journal-title":"Circulation"},{"key":"B18","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood.V85.11.3005.bloodjournal85113005","article-title":"The syndrome of hepatic veno-occlusive disease after marrow transplantation","volume":"85","author":"Bearman","year":"1995","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1289\/ehp.9023","article-title":"Risk Factors for Acute Leukemia in Children: A Review","volume":"115","author":"Belson","year":"2007","journal-title":"Environ. Health Perspect."},{"key":"B20","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S0140-6736(16)30371-3","article-title":"29Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial","volume":"388","author":"Bennett","year":"2016","journal-title":"Lancet (London, England)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1016\/j.ejpn.2017.04.1218","article-title":"Efficacy and safety of nusinersen in infants with presymptomatic spinal muscular atrophy (SMA): Interim results from the NURTURE study","volume":"21","author":"Bertini","year":"2017","journal-title":"Eur. J. Paediatric Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/0014-2999(93)90864-E","article-title":"Defibrotide, a single-stranded polydeoxyribonucleotide acting as an adenosine receptor agonist","volume":"238","author":"Bianchi","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40257-016-0238-9","article-title":"Talimogene laherparepvec (T-VEC) and other oncolytic viruses for the treatment of melanoma","volume":"18","author":"Bommareddy","year":"2017","journal-title":"Am. J. Clin Dermatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.eurpolymj.2015.03.042","article-title":"Intracellular delivery of VEGF165 encoding gene therapeutic using trifunctional copolymers of ethylene oxide and propylene oxide","volume":"68","author":"Bondar","year":"2015","journal-title":"Eur. Polymer J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1038\/bmt.2015.99","article-title":"Haploidentical HSCT: a 15-year experience at San Raffaele","volume":"50","author":"Bonini","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"B26","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/BTT.S3103","article-title":"Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID)","volume":"3","author":"Booth","year":"2009","journal-title":"Biol. Targets Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.ophtha.2009.06.045","article-title":"Introduction: understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration","volume":"116","author":"Bressler","year":"2009","journal-title":"Ophthalmology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1093\/hmg\/ddg256","article-title":"Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy","volume":"12","author":"Brichta","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"B29","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","article-title":"Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study","volume":"116","author":"Brown","year":"2009","journal-title":"Ophthalmology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1089\/humc.2013.087","article-title":"23Lessons learned from the clinical development and market authorization of Glybera","volume":"24","author":"Bryant","year":"2013","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"B31","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1089\/nat.2014.0528","article-title":"Development and application of an ultrasensitive hybridization-based ELISA method for the determination of peptide-conjugated phosphorodiamidate morpholino oligonucleotides","volume":"25","author":"Burki","year":"2015","journal-title":"Nucleic Acid Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41434-018-0013-z","article-title":"CAR-T: trailblazing the path from clinical development to the clinic","volume":"25","author":"Butera","year":"2018","journal-title":"Gene Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3109\/13506129.2016.1160882","article-title":"8Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis","volume":"23","author":"Butler","year":"2016","journal-title":"Amyloid"},{"key":"B34","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s11940-014-0316-3","article-title":"Spinal muscular atrophy: therapeutic strategies","volume":"16","author":"Castro","year":"2014","journal-title":"Curr. Treat. Options Neurol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/nm0617-652","article-title":"Viral vanguard: designing cancer-killing viruses to chase metastatic tumors","volume":"23","author":"Chakradhar","year":"2017","journal-title":"Nat. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.bbmt.2004.01.002","article-title":"Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation","volume":"10","author":"Chalandon","year":"2004","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B37","doi-asserted-by":"publisher","first-page":"9808","DOI":"10.1073\/pnas.171105098","article-title":"Treatment of spinal muscular atrophy by sodium butyrate","volume":"98","author":"Chang","year":"2001","journal-title":"Proc. Natl Acad. Sci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/mt.2009.228","article-title":"Advanced phase I\/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer","volume":"18","author":"Chawla","year":"2010","journal-title":"Mol. Ther."},{"key":"B39","first-page":"2033","article-title":"Recombinant adenovirus p53 agent injection combined with radiotherapy in treatment of nasopharyngeal carcinoma: a phase II clinical trial","volume":"83","author":"Chen","year":"2003","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.2147\/OTT.S50483","article-title":"Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives","volume":"7","author":"Chen","year":"2014","journal-title":"OncoTargets Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/j.joca.2015.06.019","article-title":"Preliminary results of a phase II randomized study to determine the efficacy and safety of genetically engineered allogeneic human chondrocytes expressing TGF-\u03b21 in patients with grade 3 chronic degenerative joint disease of the knee","volume":"23","author":"Cherian","year":"2015","journal-title":"Osteoarthr. Cartil."},{"key":"B42","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1080\/14737175.2017.1364159","article-title":"Nusinersen for the treatment of spinal muscular atrophy","volume":"17","author":"Chiriboga","year":"2017","journal-title":"Expert Rev. Neurother."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"B44","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/imr.12125","article-title":"Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma","volume":"257","author":"Chmielewski","year":"2014","journal-title":"Immunol. Rev."},{"key":"B45","doi-asserted-by":"publisher","first-page":"A170","DOI":"10.1016\/j.joca.2015.02.936","article-title":"Tissuegene-C (INVOSSA\u2122) in patients with osteoarthritis: a phase II trials","volume":"23","author":"Cho","year":"2015","journal-title":"Osteoarthr. Cartil."},{"key":"B46","doi-asserted-by":"publisher","first-page":"S148","DOI":"10.1016\/j.jcyt.2017.02.221","article-title":"A phase III clinical results of INVOSSA\u2122 (TissueGene C): a clues for the potential disease modifying OA drug","volume":"19","author":"Cho","year":"2017","journal-title":"Cytotherapy"},{"key":"B47","doi-asserted-by":"publisher","first-page":"S157","DOI":"10.1016\/j.joca.2017.02.267","article-title":"Invossa\u2122 (TISSUEGENE-C) induces an anti-inflammatory environment in the arthritic knee joints via macrophage polarization","volume":"25","author":"Choi","year":"2017","journal-title":"Osteoarthr. Cartil."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1046\/j.1365-2141.2000.02475.x","article-title":"Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study","volume":"111","author":"Chopra","year":"2000","journal-title":"Br. J. Haematol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ajo.2018.09.024","article-title":"The natural history of inherited retinal dystrophy due to biallelic mutations in the RPE65 Gene","volume":"199","author":"Chung","year":"2018","journal-title":"Am. J. Ophthalmol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1182\/blood-2016-01-688226","article-title":"Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency","volume":"128","author":"Cicalese","year":"2016","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.ymthe.2017.12.022","article-title":"Gene therapy for adenosine deaminase deficiency: a comprehensive evaluation of short- and medium-term safety","volume":"26","author":"Cicalese","year":"2018","journal-title":"Mol. Ther."},{"key":"B52","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(09)70074-9","article-title":"Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study","volume":"10","author":"Ciceri","year":"2009","journal-title":"Lancet Oncol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0140-6736(11)60756-3","article-title":"Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study","volume":"378","author":"Cirak","year":"2011","journal-title":"Lancet"},{"key":"B54","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging issues in AAV-mediated in vivo gene therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B55","first-page":"30","article-title":"International Nonproprietary Names for Pharmaceutical Substances (INN)","volume-title":"WHO Drug Information","year":"2016"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(11)61938-7","article-title":"Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial","volume":"379","author":"Corbacioglu","year":"2012","journal-title":"Lancet"},{"key":"B57","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/sj.bmt.1704329","article-title":"Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention","volume":"33","author":"Corbacioglu","year":"2004","journal-title":"Bone Marrow Transplant."},{"key":"B58","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/nn.4508","article-title":"Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy","volume":"20","author":"Corey","year":"2017","journal-title":"Nat. Neurosci."},{"key":"B59","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/mt.2015.54","article-title":"Genome editing technologies: defining a path to clinic: genomic editing: establishing preclinical toxicology standards, bethesda, maryland 10 June 2014","volume":"23","author":"Corrigan-Curay","year":"2015","journal-title":"Mol. Ther."},{"key":"B60","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1194\/jlr.M400492-JLR200","article-title":"An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis","volume":"46","author":"Crooke","year":"2005","journal-title":"J. Lipid Res."},{"key":"B61","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1365-2125.2012.04469.x","article-title":"Clinical pharmacological properties of mipomersen (K ynamro), a second generation antisense inhibitor of apolipoprotein B","volume":"76","author":"Crooke","year":"2013","journal-title":"Br J. Clin. Pharmacol."},{"key":"B62","first-page":"2309","article-title":"VEGF inhibition study in ocular neovascularization (VISION): Second year efficacy data","volume":"46","author":"D\u2019amico","year":"2005","journal-title":"Invest. Ophthalmol. Visual Sci."},{"key":"B63","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s13311-015-0337-y","article-title":"Spinal muscular atrophy therapeutics: where do we stand","volume":"12","author":"D\u2019ydewalle","year":"2015","journal-title":"Neurotherapeutics"},{"key":"B64","doi-asserted-by":"crossref","first-page":"S25.005","DOI":"10.1212\/WNL.92.15_supplement.S25.005","article-title":"Event-free survival and motor milestone achievement following AVXS-101 and nusinersen interventions contrasted to natural history for Type I spinal muscular atrophy patients","volume":"92","author":"Dabbous","year":"2019","journal-title":"Neurology"},{"key":"B65","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1076\/ocii.7.3.189.4007","article-title":"Fomivirsen\u2013a phosphorothioate oligonucleotide for the treatment of CMV retinitis","volume":"7","author":"de Smet","year":"1999","journal-title":"Ocul. Immunol. Inflammation"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1097\/00002030-200006160-00013","article-title":"Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy","volume":"14","author":"Deayton","year":"2000","journal-title":"Aids"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1056\/NEJM198205133061905","article-title":"Risk factors in head and neck cancer","volume":"306","author":"Decker","year":"1982","journal-title":"N. Engl. J. Med."},{"key":"B68","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40256-016-0210-3","article-title":"Results of an international postmarketing surveillance study of pl-VEGF165 safety and efficacy in 210 patients with peripheral arterial disease","volume":"17","author":"Deev","year":"2017","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"B69","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1177\/1074248415574336","article-title":"pCMV-vegf165 intramuscular gene transfer is an effective method of treatment for patients with chronic lower limb ischemia","volume":"20","author":"Deev","year":"2015","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"B70","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1155\/S1110724303209098","article-title":"Prodrugs for gene-directed enzyme-prodrug therapy (Suicide Gene Therapy)","volume":"2003","author":"Denny","year":"2003","journal-title":"J. Biomed. Biotechnol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.preteyeres.2017.10.004","article-title":"22Molecular genetics and emerging therapies for retinitis pigmentosa: Basic research and clinical perspectives","volume":"63","author":"Dias","year":"2018","journal-title":"Prog. Retin. Eye Res."},{"key":"B72","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-319-63904-8_1","article-title":"Viral vectors, engineered cells and the CRISPR revolution","volume":"1016","author":"Dicarlo","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1023\/A:1007657109012","article-title":"Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys","volume":"17","author":"Drolet","year":"2000","journal-title":"Pharm. Res."},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan4672","article-title":"Gene therapy comes of age","volume":"359","author":"Dunbar","year":"2018","journal-title":"Science"},{"key":"B75","doi-asserted-by":"publisher","first-page":"17113","DOI":"10.1038\/s41598-017-17180-w","article-title":"CRISPR\/Cas9 delivery with one single adenoviral vector devoid of all viral genes","volume":"7","author":"Ehrke-Schulz","year":"2017","journal-title":"Sci. Rep."},{"key":"B76","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.bbadis.2006.05.010","article-title":"Dystrophin, its interactions with other proteins, and implications for muscular dystrophy","volume":"1772","author":"Ervasti","year":"2007","journal-title":"BBA-Mol Basis Dis"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.889","article-title":"4Transthyretin familial amyloid polyneuropathy (TTR-FAP): Parameters for early diagnosis","volume":"8","author":"Escolano-Lozano","year":"2017","journal-title":"Brain Behav"},{"key":"B78","doi-asserted-by":"crossref","first-page":"14418","DOI":"10.1016\/S0021-9258(18)98701-6","article-title":"Catalytic triad residue mutation (Asp156\u2014Gly) causing familial lipoprotein lipase deficiency. Co-inheritance with a nonsense mutation (Ser447\u2014Ter) in a Turkish family","volume":"266","author":"Faustinella","year":"1991","journal-title":"J. Biol. Chem."},{"key":"B79","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3389\/fimmu.2014.00082","article-title":"30Immune Responses to AAV-Vectors, the Glybera Example from Bench to Bedside","volume":"5","author":"Ferreira","year":"2014","journal-title":"Front. Immunol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1089\/hum.2017.175","article-title":"Twenty-five years of gene therapy for ADA-SCID: from bubble babies to an approved drug","volume":"28","author":"Ferrua","year":"2017","journal-title":"Human Gene Ther."},{"key":"B81","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1056\/NEJM200002173420707","article-title":"Age-related macular degeneration","volume":"342","author":"Fine","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"B82","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"key":"B83","article-title":"Primary efficacy and safety results from the phase 3 ENDEAR study of nusinersen in infants diagnosed with spinal muscular atrophy (SMA)","author":"Finkel","year":"2017"},{"key":"B84","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1161\/ATVBAHA.111.240291","article-title":"Defibrotide interferes with several steps of the coagulation-inflammation cycle and exhibits therapeutic potential to treat severe malaria","volume":"32","author":"Francischetti","year":"2012","journal-title":"Arterioscler. Thromb. Vascul. Biol."},{"key":"B85","first-page":"458","article-title":"Retinal toxic effects associated with intravitreal fomivirsen","volume":"119","author":"Freedman","year":"2001","journal-title":"Arch. Ophthalmol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1001\/archopht.122.4.564","article-title":"Prevalence of age-related macular degeneration in the United States","volume":"122","author":"Friedman","year":"2004","journal-title":"Arch. Ophthalmol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1038\/sj.mt.6300284","article-title":"A decade of accomplishments: gene therapy and the ASGT","volume":"15","author":"Friedmann","year":"2007","journal-title":"Mol. Ther."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1111\/cas.13027","article-title":"Oncolytic virus therapy: a new era of cancer treatment at dawn","volume":"107","author":"Fukuhara","year":"2016","journal-title":"Cancer Sci."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1093\/infdis\/166.6.1223","article-title":"Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine","volume":"166","author":"Gallant","year":"1992","journal-title":"J. Infect. Dis."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/nbt1016-1002","article-title":"Big win possible for Ionis\/Biogen antisense drug in muscular atrophy","volume":"34","author":"Garber","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/gt.2012.43","article-title":"31Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial","volume":"20","author":"Gaudet","year":"2013","journal-title":"Gene Ther."},{"key":"B92","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/MOL.0b013e3283555a7e","article-title":"28Gene therapy for lipoprotein lipase deficiency","volume":"23","author":"Gaudet","year":"2012","journal-title":"Curr Opin. Lipidol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1089\/hum.2015.158","article-title":"35Long-term retrospective analysis of gene therapy with alipogene tiparvovec and its effect on lipoprotein lipase deficiency-induced pancreatitis","volume":"27","author":"Gaudet","year":"2016","journal-title":"Human Gene Ther."},{"key":"B94","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv. Drug Delivery Rev."},{"key":"B95","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jacl.2011.04.003","article-title":"Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Goldberg","year":"2011","journal-title":"J. Clin. Lipidol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1097\/00006982-200507000-00015","article-title":"HIV-associated retinopathy in the HAART era","volume":"25","author":"Goldberg","year":"2005","journal-title":"Retina"},{"key":"B97","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3892\/ijo.24.1.177","article-title":"First clinical experience using a \u2018pathotropic\u2019injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer","volume":"24","author":"Gordon","year":"2004","journal-title":"Int. J. Oncol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1517\/14712598.2010.481666","article-title":"Rexin-G, a targeted genetic medicine for cancer","volume":"10","author":"Gordon","year":"2010","journal-title":"Expert Opin. Biol. Ther."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.3892\/ijo.29.5.1053","article-title":"Pathotropic nanoparticles for cancer gene therapy Rexin-G\u2122 IV: Three-year clinical experience","volume":"29","author":"Gordon","year":"2006","journal-title":"Int. J. Oncol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"N. Engl. J Med."},{"key":"B101","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0002-9394(02)01327-2","article-title":"A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with aids1","volume":"133","author":"Group","year":"2002","journal-title":"Am. J. Ophthalmol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0002-9394(02)01326-0","article-title":"Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS1","volume":"133","author":"Group","year":"2002","journal-title":"Am. J. Ophthalmol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/S0002-9394(02)01332-6","article-title":"Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS1","volume":"133","author":"Group","year":"2002","journal-title":"Am. J. Ophthalmol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2217\/cer-2017-0068","article-title":"24Gene therapy: evidence, value and affordability in the US health care system","volume":"7","author":"Hampson","year":"2017","journal-title":"J. Comp. Eff. Res."},{"key":"B105","first-page":"2029","article-title":"Effectiveness of recombinant adenovirus p53 injection on laryngeal cancer: phase I clinical trial and follow up","volume":"83","author":"Han","year":"2003","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.15252\/emmm.201607485","article-title":"Clinical development of CAR T cells\u2014challenges and opportunities in translating innovative treatment concepts","volume":"9","author":"Hartmann","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-396879","article-title":"Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency","volume":"120","author":"Hassan","year":"2012","journal-title":"Blood"},{"key":"B108","article-title":"Adenosine deaminase deficiency","volume-title":"Encyclopedia of Molecular Mechanisms of Disease","author":"Hershfield","year":"2009"},{"key":"B109","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1093\/eurheartj\/eht015","article-title":"Diagnosis and treatment of familial hypercholesterolaemia","volume":"34","author":"Hovingh","year":"2013","journal-title":"Eur. Heart J."},{"key":"B110","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40265-017-0711-7","article-title":"Nusinersen: first global approval","volume":"77","author":"Hoy","year":"2017","journal-title":"Drugs"},{"key":"B111","doi-asserted-by":"publisher","first-page":"6737","DOI":"10.1158\/1078-0432.CCR-06-0759","article-title":"A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor","volume":"12","author":"Hu","year":"2006","journal-title":"Clin. Cancer Res"},{"key":"B112","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2217\/imt.15.35","article-title":"Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma","volume":"7","author":"Johnson","year":"2015","journal-title":"Immunotherapy"},{"key":"B113","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1177\/0883073809333535","article-title":"Oral administration of the thyrotropin-releasing hormone (TRH) analogue, taltireline hydrate, in spinal muscular atrophy","volume":"24","author":"Kato","year":"2009","journal-title":"J. Child Neurol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1245\/s10434-009-0809-6","article-title":"Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma","volume":"17","author":"Kaufman","year":"2010","journal-title":"Ann Surgical Oncol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.leukres.2016.05.025","article-title":"Considerations and challenges for patients with refractory and relapsed acute myeloid leukaemia","volume":"47","author":"Kell","year":"2016","journal-title":"Leuk Res"},{"key":"B116","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S0161-6420(03)00089-7","article-title":"The effect of cytomegalovirus retinitis on the quality of life of patients with AIDS in the era of highly active antiretroviral therapy","volume":"110","author":"Kempen","year":"2003","journal-title":"Ophthalmology"},{"key":"B117","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11940-016-0436-z","article-title":"10Current and Future Treatment Approaches in Transthyretin Familial Amyloid Polyneuropathy","volume":"18","author":"Kerschen","year":"2016","journal-title":"Curr. Treat. Options Neurol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/S1474-4422(09)70211-X","article-title":"Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study","volume":"8","author":"Kinali","year":"2009","journal-title":"Lancet Neurol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1158\/1078-0432.CCR-15-2667","article-title":"Molecular pathways: mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy","volume":"22","author":"Kohlhapp","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"B120","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.addr.2015.05.008","article-title":"Exon skipping therapy for Duchenne muscular dystrophy","volume":"87","author":"Kole","year":"2015","journal-title":"Adv. Drug Delivery Rev."},{"key":"B121","doi-asserted-by":"publisher","first-page":"16034","DOI":"10.1038\/mtm.2016.34","article-title":"Clinical development of gene therapy: results and lessons from recent successes","volume":"3","author":"Kumar","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B122","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/j.joca.2018.02.103","article-title":"INVOSSA, a first-in-class of cell and gene therapy for osteoarthritis treatment: the phase III trial","volume":"26","author":"Lee","year":"2018","journal-title":"Osteoarthr. Cartil."},{"key":"B123","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.gendis.2017.04.001","article-title":"Adenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicine","volume":"4","author":"Lee","year":"2017","journal-title":"Genes Dis."},{"key":"B124","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.1016\/j.joca.2018.02.272","article-title":"INVOSSA-K induces an anti-inflammatory environment in a rat mia model via macrophage polarization","volume":"26","author":"Lee","year":"2018","journal-title":"Osteoarthr. Cartil."},{"key":"B125","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"B126","article-title":"Basic principles of the pharmacokinetics of antisense oligonucleotide drugs","volume-title":"Antisense drug technology","author":"Levin","year":"2007"},{"key":"B127","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1517\/14712598.2015.990882","article-title":"Key points of basic theories and clinical practice in rAd-p53 (Gendicine\u2122) gene therapy for solid malignant tumors","volume":"15","author":"Li","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"B128","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2174\/1568009618666171129221503","article-title":"Oncorine, the world first oncolytic virus medicine and its update in China","volume":"18","author":"Liang","year":"2018","journal-title":"Curr. Cancer Drug Targets"},{"key":"B129","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/DDDT.S97635","article-title":"Eteplirsen in the treatment of Duchenne muscular dystrophy","volume":"11","author":"Lim","year":"2017","journal-title":"Drug Design Dev. Ther."},{"key":"B130","doi-asserted-by":"publisher","first-page":"7512","DOI":"10.1200\/JCO.2017.35.15_suppl.7512","article-title":"Clinical and biologic covariates of outcomes in ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL)","volume":"35","author":"Locke","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1182\/bloodadvances.2017006429","article-title":"The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis","volume":"1","author":"Lorentino","year":"2017","journal-title":"Blood Adv."},{"key":"B132","doi-asserted-by":"crossref","first-page":"002","DOI":"10.1212\/WNL.88.16_supplement.S13.002","article-title":"AVXS-101 Phase 1 gene therapy clinical trial in SMA Type 1: correlation between CHOP-INTEND and motor milestone achievements (S13. 002)","volume":"88","author":"Lowes","year":"2017","journal-title":"Neurology"},{"key":"B133","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.3748\/wjg.v10.i24.3634","article-title":"Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial","volume":"10","author":"Lu","year":"2004","journal-title":"World J. Gastroenterol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s40261-017-0557-5","article-title":"Nusinersen: the first option beyond supportive care for spinal muscular atrophy","volume":"37","author":"Maharshi","year":"2017","journal-title":"Clin Drug Investig."},{"key":"B135","article-title":"Biochemistry and physiology of lipid and lipoprotein metabolism","volume-title":"Principles and Practice of Endocrinology and Metabolism","author":"Mahley","year":"2001"},{"key":"B136","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1006\/mthe.2002.0638","article-title":"Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study","volume":"6","author":"M\u00e4kinen","year":"2002","journal-title":"Mol. Ther."},{"key":"B137","doi-asserted-by":"publisher","first-page":"1601484","DOI":"10.1080\/20016689.2019.1601484","article-title":"Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients","volume":"7","author":"Malone","year":"2019","journal-title":"J. Mark. Access Health Policy"},{"key":"B138","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/1471-2202-10-142","article-title":"Subcutaneous administration of TC007 reduces disease severity in an animal model of SMA","volume":"10","author":"Mattis","year":"2009","journal-title":"BMC Neurosci."},{"key":"B139","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0049006","article-title":"Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy","volume":"7","author":"Mcgowan","year":"2012","journal-title":"PloS one"},{"key":"B141","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ana.24555","article-title":"Longitudinal effect of eteplirsen versus historical control on ambulation in D uchenne muscular dystrophy","volume":"79","author":"Mendell","year":"2016","journal-title":"Ann. Neurol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/j.ejpn.2017.04.1216","article-title":"AVXS-101 Phase 1 gene therapy clinical trial in SMA Type 1: Event free survival and achievement of developmental milestones","volume":"21","author":"Mendell","year":"2017","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/mus.23810","article-title":"Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy","volume":"48","author":"Mendell","year":"2013","journal-title":"Muscle Nerve"},{"key":"B144","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann. Neurol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.nmd.2012.11.001","article-title":"Stem cells in severe infantile spinal muscular atrophy","volume":"22","author":"Mercuri","year":"2012","journal-title":"Neuromuscul. Disord."},{"key":"B146","doi-asserted-by":"publisher","first-page":"S210","DOI":"10.1016\/j.nmd.2017.06.418","article-title":"Efficacy and safety of nusinersen in children with later-onset spinal muscular atrophy (SMA): end of study results from the phase 3 CHERISH study","volume":"27","author":"Mercuri","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"B147","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.nmd.2015.10.006","article-title":"Patterns of disease progression in type 2 and 3 SMA: implications for clinical trials","volume":"26","author":"Mercuri","year":"2016","journal-title":"Neuromuscul. Disord."},{"key":"B148","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1080\/13816810.2018.1533027","article-title":"Gene therapy for RPE65-related retinal disease","volume":"39","author":"Miraldi Utz","year":"2018","journal-title":"Ophthalmic Genet."},{"key":"B149","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/ejhg.2012.301","article-title":"Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK)","volume":"21","author":"Moat","year":"2013","journal-title":"Eur. J. Human Genet."},{"key":"B150","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1182\/blood.V128.22.672.672","article-title":"Allogeneic genetically modified T Cells (HSV-TK) as adjunctive treatment in haploidentical hematopoietic stem-cell transplantation (haplo-HSCT) of adult patients with high-risk hematological malignancies: a pair-matched analysis from the acute Leukemia working party of EBMT","volume":"128","author":"Mohty","year":"2016","journal-title":"Blood"},{"key":"B151","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/bmt.2015.52","article-title":"Sinusoidal obstruction syndrome\/veno-occlusive disease: current situation and perspectives\u2014a position statement from the European Society for Blood and Marrow Transplantation (EBMT)","volume":"50","author":"Mohty","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"B152","first-page":"1023","article-title":"Guide for morpholino users: toward therapeutics","volume":"3","author":"Moulton","year":"2016","journal-title":"J. Drug Discov. Dev. Deliv."},{"key":"B153","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1128\/AAC.42.4.971","article-title":"Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922)","volume":"42","author":"Mulamba","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"B154","doi-asserted-by":"crossref","DOI":"10.1038\/nrd.2017.17","volume-title":"2016 EMA drug approval recommendations","author":"Mullard","year":"2017"},{"key":"B155","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood.V128.22.LBA-6.LBA-6","article-title":"Kte-C19 (anti-CD19 CAR T Cells) induces complete remissions in patients with refractory diffuse large B-Cell Lymphoma (DLBCL): results from the pivotal Phase 2 Zuma-1","volume":"128","author":"Neelapu","year":"2016","journal-title":"Blood"},{"key":"B156","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B157","first-page":"6359","article-title":"Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial","volume":"60","author":"Nemunaitis","year":"2000","journal-title":"Cancer Res."},{"key":"B158","first-page":"411","article-title":"E6-Specific detection and typing of human Papillomaviruses in oral cavity specimens from Iranian patients","volume":"21","author":"Nikoo","year":"2017","journal-title":"Iran. Biomed. J."},{"key":"B159","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/nbt0104-3","article-title":"China approves first gene therapy","volume":"22","author":"Pearson","year":"2004","journal-title":"Nat. Biotechnol."},{"key":"B160","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1089\/hum.2005.16.1016","article-title":"Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers","volume":"16","author":"Peng","year":"2005","journal-title":"Human Gene Ther."},{"key":"B161","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1007\/s00415-017-8708-4","article-title":"3Transthyretin familial amyloid polyneuropathy: an update","volume":"265","author":"Plante-Bordeneuve","year":"2018","journal-title":"J. Neurol."},{"key":"B162","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/gt.2017.59","article-title":"Spinraza\u2014a rare disease success story","volume":"24","author":"Prakash","year":"2017","journal-title":"Gene. Ther."},{"key":"B163","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1002\/cncr.29998","article-title":"FDA approves new treatment of metastatic melanoma","volume":"122","author":"Printz","year":"2016","journal-title":"Cancer"},{"key":"B164","doi-asserted-by":"publisher","first-page":"9029","DOI":"10.1200\/jco.2014.32.15_suppl.9029","article-title":"Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma","volume":"32","author":"Puzanov","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"B165","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2012.02.019","article-title":"Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment","volume":"223","author":"Raal","year":"2012","journal-title":"Atherosclerosis"},{"key":"B166","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"key":"B167","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/ceo.13416","article-title":"Gene therapy and the adeno associated virus in the treatment of genetic and acquired ophthalmic diseases in humans: trials, future directions and safety considerations","volume":"47","author":"Ramlogan-Steel","year":"2018","journal-title":"Clin. Exp. Ophthalmol."},{"key":"B168","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.18553\/jmcp.2018.24.12-a.s3","article-title":"Gene therapy for spinal muscular atrophy: an emerging treatment option for a devastating disease","volume":"24","author":"Rao","year":"2018","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"B169","article-title":"FDA Approves First Oncolytic Virus Therapy: Imlygic for Melanoma","author":"Reach","year":"2015"},{"key":"B170","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/sj.cgt.7700819","article-title":"Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU\/leucovorin","volume":"12","author":"Reid","year":"2005","journal-title":"Cancer Gene Ther."},{"key":"B171","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1517\/14740338.2012.749855","article-title":"Drug safety evaluation of defibrotide","volume":"12","author":"Richardson","year":"2013","journal-title":"Expert Opin. Drug Saf."},{"key":"B172","first-page":"737","article-title":"Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population","volume":"92","author":"Richardson","year":"1998","journal-title":"Blood"},{"key":"B173","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1182\/blood-2015-10-676924","article-title":"Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure","volume":"127","author":"Richardson","year":"2016","journal-title":"Blood"},{"key":"B174","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.bbmt.2010.02.009","article-title":"Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial","volume":"16","author":"Richardson","year":"2010","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B175","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/CRD.0b013e31823424be","article-title":"Mipomersen: a safe and effective antisense therapy adjunct to statins in patients with hypercholesterolemia","volume":"20","author":"Ricotta","year":"2012","journal-title":"Cardiol. Rev."},{"key":"B176","volume-title":"34The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal","author":"Robert Hettle","year":"2017"},{"key":"B177","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1080\/10428194.2017.1387905","article-title":"Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL","volume":"59","author":"Roberts","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"B178","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1242\/jcs.114.5.853","article-title":"The splice variants of vascular endothelial growth factor (VEGF) and their receptors","volume":"114","author":"Robinson","year":"2001","journal-title":"J. Cell Sci."},{"key":"B179","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.trsl.2017.07.003","article-title":"Chimeric antigen receptor T-cell therapy for glioblastoma","volume":"187","author":"Rodriguez","year":"2017","journal-title":"Transl Res"},{"key":"B180","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.bcp.2008.11.005","article-title":"Cross-species comparison of in vivo PK\/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100","volume":"77","author":"Rosie","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"B181","doi-asserted-by":"publisher","first-page":"20556","DOI":"10.1074\/jbc.273.32.20556","article-title":"2\u2032-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165) inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain","volume":"273","author":"Ruckman","year":"1998","journal-title":"J. Biol. Chem."},{"key":"B182","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/21678707.2018.1508340","article-title":"17Voretigene neparvovec-rzyl for the treatment of biallelic RPE65 mutation\u2013associated retinal dystrophy","volume":"6","author":"Russell","year":"2018","journal-title":"Expert Opin. Orphan Drugs"},{"key":"B183","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"19Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet (London, England)"},{"key":"B184","doi-asserted-by":"crossref","DOI":"10.1161\/ATVBAHA.114.304549","article-title":"Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein (a) in various populations with hypercholesterolemia: results of 4 phase III trials","volume-title":"Arteriosclerosis, thrombosis, and vascular biology","author":"Santos","year":"2015"},{"key":"B185","doi-asserted-by":"publisher","first-page":"CD011346","DOI":"10.1002\/14651858.CD011346.pub2","article-title":"Aflibercept for neovascular age-related macular degeneration","volume":"2","author":"Sarwar","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"B186","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.clml.2017.07.213","article-title":"Primary analysis of juliet: a global, pivotal, phase 2 Trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"130","author":"Schuster","year":"2017","journal-title":"Blood"},{"key":"B187","doi-asserted-by":"publisher","first-page":"5763","DOI":"10.1200\/JCO.2009.24.3675","article-title":"Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor\u2013encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma","volume":"27","author":"Senzer","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"B188","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/joa.12083","article-title":"Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease","volume":"224","author":"Shababi","year":"2014","journal-title":"J. Anatomy"},{"key":"B189","doi-asserted-by":"publisher","first-page":"341","DOI":"10.4161\/rna.6.3.8723","article-title":"A short antisense oligonucleotide masking a unique intronic motif prevents skipping of a critical exon in spinal muscular atrophy","volume":"6","author":"Singh","year":"2009","journal-title":"RNA Biol."},{"key":"B190","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jocit.2016.08.001","article-title":"Chimeric antigen receptor (CAR) T cell therapy for malignant cancers: summary and perspective","volume":"2","author":"Smith","year":"2016","journal-title":"J. Cell. Immunother."},{"key":"B191","doi-asserted-by":"publisher","first-page":"CD005139","DOI":"10.1002\/14651858.CD005139.pub3","article-title":"Anti-vascular endothelial growth factor for neovascular age-related macular degeneration","volume":"8","author":"Solomon","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"B192","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1038\/mt.2016.188","article-title":"Eteplirsen approved for Duchenne muscular dystrophy: the FDA faces a difficult choice","volume":"24","author":"Stein","year":"2016","journal-title":"Mol. Ther."},{"key":"B193","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1161\/CIRCULATIONAHA.112.104125","article-title":"Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease","volume":"126","author":"Stein","year":"2012","journal-title":"Circulation"},{"key":"B194","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.bbmt.2016.04.011","article-title":"Defibrotide for treatment of severe veno-occlusive disease in pediatrics and adults: an exploratory analysis using data from the Center for International Blood and Marrow Transplant Research","volume":"22","author":"Strouse","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B195","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJM199201233260401","article-title":"Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis","volume":"326","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"B196","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13023-015-0326-6","article-title":"Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study","volume":"10","author":"Suhr","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"B197","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1089\/oli.1.1997.7.187","article-title":"Morpholino antisense oligomers: design, preparation, and properties","volume":"7","author":"Summerton","year":"1997","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"B198","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/humu.20111","article-title":"Molecular and functional analysis of intragenic SMN1 mutations in patients with spinal muscular atrophy","volume":"25","author":"Sun","year":"2005","journal-title":"Hum. Mutat."},{"key":"B199","doi-asserted-by":"publisher","first-page":"e577","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: a comprehensive review and 2017 update","volume":"7","author":"Terwilliger","year":"2017","journal-title":"Blood Cancer J."},{"key":"B200","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1016\/j.jacc.2013.07.081","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Thomas","year":"2013","journal-title":"J. Am. Col. Cardiol."},{"key":"B201","doi-asserted-by":"publisher","first-page":"680","DOI":"10.3324\/haematol.2015.141119","article-title":"How to select the best available related or unrelated donor of hematopoietic stem cells","volume":"101","author":"Tiercy","year":"2016","journal-title":"Haematologica"},{"key":"B202","unstructured":"FDA approves new orphan drug Kynamro to treat inherited cholesterol disorder [Online]2013"},{"key":"B203","unstructured":"FDA grants accelerated approval to first drug for Duchenne muscular dystrophy [Online]2016"},{"key":"B204","unstructured":"FDA briefing document: Oncologic Drugs Advisory Committee meeting; BLA 125646; Tisagenlecleucel2017"},{"key":"B205","first-page":"2018","article-title":"18Voretigene Neparvovec: An Emerging Gene Therapy for the Treatment of Inherited Blindness","author":"Utsav Patel","year":""},{"key":"B206","first-page":"854","article-title":"Pigmentary retinopathy associated with intravitreal fomivirsen","volume":"120","author":"Uwaydat","year":"2002","journal-title":"Arch. Ophthalmol."},{"key":"B207","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1182\/blood-2012-01-405670","article-title":"T-cell suicide gene therapy prompts thymic renewal in adults after hematopoietic stem cell transplantation","volume":"120","author":"Vago","year":"2012","journal-title":"Blood"},{"key":"B208","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1023\/A:1007619323939","article-title":"The incidence of cytomegalovirus (CMV) antigenemia and CMV disease is reduced by highly active antiretroviral therapy","volume":"16","author":"Varani","year":"2000","journal-title":"Eur. J. Epidemiol."},{"key":"B209","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1080\/13696998.2016.1275652","article-title":"The budget impact and cost-effectiveness of defibrotide for treatment of veno-occlusive disease with multi-organ dysfunction in patients post-hematopoietic stem cell transplant","volume":"20","author":"Veenstra","year":"2017","journal-title":"J. Med. Econ."},{"key":"B210","first-page":"673","article-title":"Technology evaluation: pegaptanib, Eyetech\/Pfizer","volume":"5","author":"Vinores","year":"2003","journal-title":"Curr. Opin. Mol. Ther."},{"key":"B211","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.copbio.2018.01.025","article-title":"A guide to manufacturing CAR T cell therapies","volume":"53","author":"Vormittag","year":"2018","journal-title":"Curr Opin. Biotechnol."},{"key":"B212","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11940-019-0568-z","article-title":"Current treatment options in neurology\u2014SMA therapeutics","volume":"21","author":"Waldrop","year":"2019","journal-title":"Curr. Treat. Options Neurol."},{"key":"B213","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3389\/fimmu.2016.00314","article-title":"Adenosine Deaminase Deficiency \u2013 More Than Just an Immunodeficiency","volume":"7","author":"Whitmore","year":"2016","journal-title":"Front. Immunol."},{"key":"B214","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1089\/hum.2005.16.1014","article-title":"Gendicine: The first commercial gene therapy product; Chinese translation of editorial","volume":"16","author":"Wilson","year":"2005","journal-title":"Human Gene Ther."},{"key":"B215","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ophtha.2007.03.008","article-title":"The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis","volume":"115","author":"Wong","year":"2008","journal-title":"Ophthalmology"},{"key":"B216","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Global Health"},{"key":"B217","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/s41582-018-0065-0","article-title":"2FDA approves patisiran to treat hereditary transthyretin amyloidosis","volume":"14","author":"Wood","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"B218","first-page":"1666","article-title":"Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus","volume":"23","author":"Xia","year":"2004","journal-title":"Ai zheng"},{"key":"B219","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.clinthera.2013.11.006","article-title":"Molecular therapeutic strategies for spinal muscular atrophies: current and future clinical trials","volume":"36","author":"Zanetta","year":"2014","journal-title":"Clin. Ther."},{"key":"B220","first-page":"2023","article-title":"Treatment of head and neck squamous cell carcinoma by recombinant adenovirus-p53 combined with radiotherapy: a phase II clinical trial of 42 cases","volume":"83","author":"Zhang","year":"2003","journal-title":"Zhonghua yi xue za zhi"},{"key":"B221","first-page":"426","article-title":"Recombinant adenovirus-p53 gene therapy combined with radiotherapy for head and neck squamous-cell carcinoma","volume":"27","author":"Zhang","year":"2005","journal-title":"Zhonghua zhong liu za zhi [Chinese journal of oncology]"},{"key":"B222","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1089\/hum.2017.218","article-title":"The first approved gene therapy product for cancer ad-p53 (gendicine): 12 years in the clinic","volume":"29","author":"Zhang","year":"2018","journal-title":"Human Gene Ther."}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fgene.2019.00868\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T20:27:09Z","timestamp":1721766429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fgene.2019.00868\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,25]]},"references-count":222,"alternative-id":["10.3389\/fgene.2019.00868"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2019.00868","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,25]]},"article-number":"868"}}